HIV-2 Protease resistance defined in yeast cells

Retrovirology

Table 2 Protease Inhibitor treatment received by HIV-2 infected individuals

Patient	Protease Inhibitor	CD4 (cells/μl)	Viral load (Log₁₀)	Therapeutic failure
MRT-1	NFV	173	3.9	yes
MRT-7	RTV, NFV	335	4.5	yes
MRT-8	SQV, IDV/rtv, NFV	211	5.3	yes
MRT-20	IDV, NFV	229	2	no
MRT-22	NFV, LPV	106	3.9	yes
MRT-25	IDV, LPV/rtv, APV/rtv	82	3.9	yes
MRT-29	NFV	53	4.5	yes

The Protease Inhibitors sequentially received by each patient from a previous cohort [6] are listed. (For this study, blood samples were taken on April 2002 for MRT-1, March 2002 for MRT-7, June 2003 for MRT-8, December 2000 for MRT-20, June 2002 for MRT-22, February 2003 for MRT-25, and May 2002 for MRT-29). Therapeutic failure was defined when the CD4 counts were < 200 and/or the viral load remained unchanged after treatment [6].

ISSN: 1742-4690